R
Roel Huis in ‘t Veld
Director, Kriya Materials · Week of September 28, 2026
In a smaller company every product has to be both
Last Friday BASF confirmed it is in exploratory talks with RAG-Stiftung and Evonik about a takeover of Evonik, adding that "the course and outcome of these exploratory talks remain open at this stage."
Evonik confirmed a non-binding approach and said it will not comment beyond what the law requires. Three days earlier Evonik had announced 3,200 job cuts, about 2,150 of them in Germany, and a new sorting of its businesses into growth drivers and cash generators.
Interim CEO Claus Rettig said what most of the industry only says over dinner: "We are in a structural and economic crisis in our industry."
I have been running a specialty materials company since 2011 and I read these two announcements differently from the analysts. The sorting is the interesting part, not the deal.
In a large group you can label a business a cash generator, stop investing in it and use the money elsewhere. In a company our size that option does not exist. The product that pays this month's salaries is the same product that has to fund the next development, so every formulation has to earn its place on both counts at the same time. It sounds like a handicap, but it is a discipline: you find out within a quarter which products are neither, and you stop them before they become a restructuring programme.
The second thing I read is what consolidation upstream does to a formulator. Fewer suppliers means fewer people willing to make the small special grade you qualified your product on. Anyone who has had a raw material discontinued after a merger knows the sequence: a polite letter, a last-time-buy date and a requalification project nobody budgeted for. If BASF and Evonik combine, portfolios will be rationalised, that is the whole point of combining, and the small volumes go first.
That is also where the opportunity is. When the big houses prune, customers are left holding specifications that nobody wants to supply anymore, and that is precisely the work a small specialist can still say yes to. Two conditions. Your own finances have to be boring enough to survive qualification cycles that run longer than the sales forecast, and you must not fall in love with one customer. I have learned the hard way what happens to a small company when a large customer disappears overnight; technical excellence does not compensate for that. My question therefore nowadays, what bears the bigger risk, doing business with the large corporate supplier who just seizes production for restructuring reasons, or the small agile company running the extra mile to do what it takes, but with a balance sheet of a smaller size then any of the BU's it deels with at the corporate client.
Rettig talks about using the polycrisis to change old structures. Large companies need a crisis to do that. Small ones have no structures to change, only habits, and habits you can change on a Monday morning. Whether the deal happens or not, the sorting has started, and every supplier to these two companies will be sorted with them.
BASF release, 25 Sept 2026 — https://www.basf.com/global/en/media/news-releases/2026/09/p-26-172
Evonik confirms non-binding approach (RTTNews, 25 Sept) — https://www.rttnews.com/3694022/evonik-confirms-receipt-of-non-binding-takeover-offer-from-basf-but-no-talks-taking-place.aspx
Evonik sharpens growth strategy, 22 Sept 2026 — https://www.evonik.com/en/news/press-releases/2026/09/evonik-sharpens-growth-strategy.html